Jan 3, 2012 · BCM, also known as IK-5001, is being investigated to prevent ventricular remodeling and subsequent congestive heart failure (CHF) following acute myocardial infarction (AMI). Ventricular...

Jan 4, 2012 · Ikaria has commenced its global PRESERVATION I clinical trial for the Bioabsorbable Cardiac Matrix (BCM). BCM, also known as IK-5001, is being investigated to prevent ventricular remodeling and subsequent congestive heart failure following acute myocardial infarction.

Jan 3, 2012 · BCM, also known as IK-5001, is being investigated to prevent ventricular remodeling and subsequent congestive heart failure (CHF) following acute myocardial infarction (AMI). Ventricular remodeling is the structural alteration of the damaged heart muscle that occurs following an acute heart attack.

Jan 3, 2012 · Ikaria Inc., which acquired the license for continuation of development and commercialization of BL-1040 from BioLineRx in July 2009, is now leading BL-1040's clinical development as...

Jul 27, 2015 · Bellerophon Therapeutics ($BLPH) spun out of private-equity-backed Ikaria to develop two programs, but now one of these has failed in its first major trial. It reported top-line results of a trial...

Aug 16, 2016 · Bioabsorbable cardiac matrix (BCM) is a novel device that attenuates adverse left ventricular (LV) remodeling after large myocardial infarctions in experimental models. This study aimed to analyze whether BCM, compared with saline control, would result in less LV dilation and fewer adverse clinical events between baseline and 6 months.

Mar 7, 2012 · In June 2009, BioLineRx out-licensed BL-1040 to Ikaria Inc. for continuation of development and commercialization of bioabsorbable cardiac matrix, or BCM (previously named IK-5001). In December 2011, Ikaria commenced the PRESERVATION I clinical trial, a CE mark registration trial for BCM (BL-1040).

Ikaria, Inc. acquired the exclusive worldwide license to develop and commercialize BCM from BioLineRx in 2009. In January 2012, BioLineRx announced the commencement of the PRESERVATION I clinical trial, a CE Mark registration trial of BCM (BL-1040) led by Ikaria.

Feb 13, 2015 · BCM is currently in a placebo-controlled trial that's expected to support a CE mark for the prevention of cardiac remodeling, which often leads to congestive heart failure following a type of...

Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive...